METTL3 and breast carcinoma: METTL3 emerges as a clinically validated prognostic and immunoregulatory biomarker in breast cancer, whereas METTL14 is correlated with both survival outcomes and tumor-infiltrating lymphocyte dynamics in rectal adenocarcinoma [243].